Claire Verschraegen

Oncology
2050 Kenny Rd
Columbus, OH 43221

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.

Journal: Research square
Published: September 03, 2026

Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review.

Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review.

Journal: Frontiers in oncology
Published: July 31, 2026

Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review.

Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review.

Journal: Frontiers in oncology
Published: June 06, 2026

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

How the Ketogenic Diet Shapes the Microbiome to Influence Cancer Immunotherapy Outcomes: An Exploration of Clinical Trials and Their Results.

Journal: Nutrition and cancer
Published: May 04, 2026

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

Journal: The oncologist
Published: March 24, 2026

Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma.

Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma.

Journal: Cancers
Published: January 30, 2026

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Journal: Cancer investigation
Published: October 10, 2025

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641.

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641.

Journal: Translational andrology and urology
Published: September 30, 2025

Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.

Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.

Journal: Journal of the American Academy of Dermatology
Published: September 28, 2025

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report.

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report.

Journal: The oncologist
Published: September 25, 2025
Showing 1-12 of 98

Last Updated: 09/26/2026